{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:58:56Z","timestamp":1794567536525,"version":"4.9.1"},"reference-count":59,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2002,11,7]],"date-time":"2002-11-07T00:00:00Z","timestamp":1036627200000},"content-version":"vor","delay-in-days":341,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Contact Dermatitis"],"published-print":{"date-parts":[[2001,12]]},"abstract":"<jats:p>Skin testing with a suspected drug has been reported to be helpful in determining the cause of cutaneous adverse drug reactions (CADR). Many isolated reports of positive drug skin tests are published, but without detailed information concerning the clinical features of the CADR and the method used in performing drug skin tests, such data are not very informative. A working party of the European Society of Contact Dermatitis (ESCD) for the study of skin testing in investigating cutaneous adverse drug reactions, has proposed the herein\u2010reported guidelines for performing skin testing in CADR in order to standardize these procedures. In each reported case, the imputability of each drug taken at the onset of the CADR and a highly detailed description and characterization of the dermatitis need to be given. Drug skin tests are performed 6 weeks to 6 months after complete healing of the CADR. Drug patch tests are performed according to the methods used in patch testing in studying contact dermatitis. The commercialized form of the drug used by the patient is tested diluted at 30% pet. (pet.) and\/or water (aq.). The pure drug is tested diluted at 10% in pet. or aq. In severe CADR, drug patch tests are performed at lower concentrations. It is also of value to test on the most affected site of the initial CADR. Drug prick tests are performed on the volar forearm skin with the commercialized form of the drug, but with sequential dilutions in cases of urticaria. Intradermal tests (IDT) are performed with sterile sequential dilutions (10\u20134, 10\u20133, 10\u20132, 10\u20131) of a pure sterile or an injectable form of the suspected drug with a small volume of 0.04 ml. Drug skin tests need to be read at 20 min and also later at D2 and D4 for patch tests, at D1 for prick tests and IDT. All these tests also need to be read at 1 week. The success of skin tests varies with the drug tested, with a high % of positive results, for example, with betalactam antibiotics, pristinamycin, carbamazepine and tetrazepam on patch testing, or with betalactam antibiotics and heparins on delayed readings of IDT. The results of drug skin tests also depend on the clinical features of the CADR. The use of appropriate control patients is necessary to avoid false\u2010positive results.<\/jats:p>","DOI":"10.1034\/j.1600-0536.2001.450601.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T13:02:15Z","timestamp":1047387735000},"page":"321-328","source":"Crossref","is-referenced-by-count":431,"title":["Guidelines for performing skin tests withdrugs in the investigation of cutaneous adverse drug reactions"],"prefix":"10.1111","volume":"45","author":[{"given":"Annick","family":"Barbaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarida","family":"Gon\u00e7alo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derk","family":"Bruynzeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Bircher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,11,7]]},"reference":[{"key":"e_1_2_11_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02313.x"},{"key":"e_1_2_11_3_2","first-page":"47","article-title":"Tests cutan\u00e9s dans l'exploration des toxidermies suppos\u00e9es de m\u00e9canisme immuno\u2010allergique","volume":"184","author":"Barbaud A","year":"2000","journal-title":"Bull Acad Natle Med"},{"key":"e_1_2_11_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.1990.tb01631.x"},{"key":"e_1_2_11_5_2","first-page":"196","article-title":"Patch testing in drug eruptions","volume":"8","author":"Bruynzeel D P","year":"1989","journal-title":"Sem Dermatol"},{"key":"e_1_2_11_6_2","first-page":"s22","article-title":"Epicutaneous patch testing in drug eruptions","volume":"42","author":"Gon\u00e7alo M","year":"2000","journal-title":"Contact Dermatitis"},{"key":"e_1_2_11_7_2","first-page":"119","article-title":"Skin tests in the diagnosis of maculopapular drug eruptions","volume":"6","author":"Bruynzeel D P","year":"1987","journal-title":"Sem Dermatol"},{"key":"e_1_2_11_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(85)90918-3"},{"key":"e_1_2_11_9_2","doi-asserted-by":"publisher","DOI":"10.3109\/09546639909056032"},{"key":"e_1_2_11_10_2","first-page":"287","article-title":"Terminology of contact dermatitis","volume":"50","author":"Wilkinson D S","year":"1970","journal-title":"Acta Dermato-venereologica"},{"key":"e_1_2_11_11_2","first-page":"67","volume-title":"Progr\u00e8s en dermato\u2010allergologie","author":"Gon\u00e7alo M","year":"1998"},{"key":"e_1_2_11_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1987.tb05879.x"},{"key":"e_1_2_11_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1994.tb01900.x"},{"key":"e_1_2_11_14_2","first-page":"s30","article-title":"Topical provocation in 9 cases of fixed drug eruption due to non\u2010steroidal anti\u2010inflammatory drugs","volume":"42","author":"Oliveira H S","year":"2000","journal-title":"Contact Dermatitis"},{"key":"e_1_2_11_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1999.tb05989.x"},{"key":"e_1_2_11_16_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0536.2001.440409-15.x"},{"key":"e_1_2_11_17_2","first-page":"307","article-title":"Positive lesional patch tests in fixed drug eruptions from nimesulide","volume":"43","author":"Robalo\u2010Cordeiro M","year":"2000","journal-title":"Contact Dermatitis"},{"key":"e_1_2_11_18_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0536.2001.440409-15.x"},{"key":"e_1_2_11_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1995.tb02099.x"},{"key":"e_1_2_11_20_2","volume-title":"Skin reactions to drugs","author":"Kaupinnen K","year":"1998"},{"key":"e_1_2_11_21_2","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/archderm.1989.01670140151033","article-title":"Patch testing with carbamazepine: reinduction of an exfoliative dermatitis","volume":"125","author":"Vaillant L","year":"1989","journal-title":"Arch Dermatol"},{"key":"e_1_2_11_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1991.tb01657.x"},{"key":"e_1_2_11_23_2","first-page":"312","article-title":"Flare\u2010up reaction of pseudoephedrine baboon syndrome after positive patch test","volume":"42","author":"Sanchez T S","year":"2000","journal-title":"Contact Dermatitis"},{"key":"e_1_2_11_24_2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/BF02771765","article-title":"Place of excipients in drug related allergy","volume":"13","author":"Barbaud A","year":"1995","journal-title":"Clin Rev Allergol Immunol"},{"key":"e_1_2_11_25_2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/archderm.1997.03890400081011","article-title":"R\u00f4le of delayed cellular hypersensitivity and adhesion molecules in maculopapular rashes induced by amoxicillin","volume":"133","author":"Barbaud A","year":"1997","journal-title":"Arch Dermatol"},{"key":"e_1_2_11_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1996.tb02364.x"},{"key":"e_1_2_11_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1992.tb03281.x"},{"key":"e_1_2_11_28_2","doi-asserted-by":"publisher","DOI":"10.1159\/000249468"},{"key":"e_1_2_11_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(99)70197-1"},{"key":"e_1_2_11_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1995.tb05066.x"},{"key":"e_1_2_11_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1991.tb00560.x"},{"key":"e_1_2_11_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/1046-199X(95)90059-4"},{"key":"e_1_2_11_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1996.tb01169.x"},{"key":"e_1_2_11_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1990.tb01457.x"},{"key":"e_1_2_11_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1996.tb02108.x"},{"key":"e_1_2_11_36_2","first-page":"25","article-title":"R\u00e9action d'hypersensibilit\u00e9 retard\u00e9e aux h\u00e9parines et h\u00e9parino\u00efdes","volume":"128","author":"Figarella I","year":"2001","journal-title":"Ann Dermato-v\u00e9n\u00e9r\u00e9ologica"},{"key":"e_1_2_11_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1996.tb02135.x"},{"key":"e_1_2_11_38_2","first-page":"283","article-title":"Patch test diagnosis in carbamazepine erythroderma","volume":"8","author":"Silva R","year":"1982","journal-title":"Contact Dermatitis"},{"key":"e_1_2_11_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1985.tb01040.x"},{"key":"e_1_2_11_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1989.tb03152.x"},{"key":"e_1_2_11_41_2","doi-asserted-by":"publisher","DOI":"10.1159\/000247078"},{"key":"e_1_2_11_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1991.tb01814.x"},{"key":"e_1_2_11_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1993.tb03560.x"},{"key":"e_1_2_11_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1995.tb02098.x"},{"key":"e_1_2_11_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1996.tb02255.x"},{"key":"e_1_2_11_46_2","first-page":"31","article-title":"Delayed hypersensitivity to diltiazem in two patients","volume":"69","author":"Romano A","year":"1992","journal-title":"Ann Allergy"},{"key":"e_1_2_11_47_2","first-page":"498","article-title":"Investigations allergologiques dans une toxidermie au diltiazem (Tildiem 300 LPR)","volume":"48","author":"Barbaud A","year":"1993","journal-title":"Th\u00e9rapie"},{"key":"e_1_2_11_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(74)90417-6"},{"key":"e_1_2_11_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1997.tb00397.x"},{"key":"e_1_2_11_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1990.tb01587.x"},{"key":"e_1_2_11_51_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1992.tb00259.x"},{"key":"e_1_2_11_52_2","first-page":"116","article-title":"Allergic skin reaction to tetrazepam detected by patch testing","volume":"3","author":"Tomb R","year":"1993","journal-title":"Eur J Dermatol"},{"key":"e_1_2_11_53_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1990.tb03139.x"},{"key":"e_1_2_11_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(99)70439-2"},{"key":"e_1_2_11_55_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1994.tb00809.x"},{"key":"e_1_2_11_56_2","first-page":"214","article-title":"Allergies cutan\u00e9es et insulinoth\u00e9rapie. Aspects r\u00e9cents, conduite \u00e0 tenir","volume":"123","author":"Barbaud A","year":"1996","journal-title":"Ann Dermatol Venereol"},{"key":"e_1_2_11_57_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1994.tb02013.x"},{"key":"e_1_2_11_58_2","first-page":"75","volume-title":"Progr\u00e8s en dermato\u2010allergologie","author":"Barbaud A","year":"1998"},{"key":"e_1_2_11_59_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1993.tb03555.x"},{"key":"e_1_2_11_60_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0536.2001.450502.x"}],"container-title":["Contact Dermatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0536.2001.450601.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0536.2001.450601.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1600-0536.2001.450601.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T19:36:02Z","timestamp":1698780962000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1034\/j.1600-0536.2001.450601.x"}},"subtitle":["Proposed by the Working party of the ESCD for the study of skin testing in investigating cutaneous adverse drug reactions"],"short-title":[],"issued":{"date-parts":[[2001,12]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2001,12]]}},"alternative-id":["10.1034\/j.1600-0536.2001.450601.x"],"URL":"https:\/\/doi.org\/10.1034\/j.1600-0536.2001.450601.x","archive":["Portico"],"relation":{},"ISSN":["0105-1873","1600-0536"],"issn-type":[{"value":"0105-1873","type":"print"},{"value":"1600-0536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,12]]}}}